Mission and Vision

The International Plasma and Fractionation Association (IPFA) is the international umbrella association promoting the interests and activities of its member organisations involved in the collection of human blood and plasma, and the manufacture and supply of essential medicines derived from human plasma.

 

Essential medicines

The World Health Organization (WHO) has underlined the importance of Plasma Derived Medicinal Products (PDMPs) for global health care by including a number of PDMPs on the WHO Model List of Essential Medicines (2). Such products include Anti-D immunoglobulin, anti-rabies immunoglobulin, anti-tetanus immunoglobulin, normal immunoglobulin for intramuscular, for intravenous and subcutaneous use, coagulation factor VIII and coagulation factor IX. These are identified as essential medicinal products and governments “should make sure that all people can access the medicines they need, when and where they need them. This is vital to countries’ progress towards universal health coverage”.

 

Voluntary Non Remunerated Blood Donation

IPFA and its member organisations strive to ensure greater global and national access to these lifesaving Plasma Derived Medicinal Products for patients and healthcare providers based on a preference for and commitment to the “gift model” of blood and plasma donation without remuneration (Voluntary Non Remunerated Blood Donation, VNRBD).

 

Not for Profit

IPFA supports the “not-for-profit business model” where no financial gain flows from the donation to external or individual shareholders.

 

Activities & Initiatives

Role IPFA

  • Acts to create bridges and an effective liaison between blood/plasma collection centres, plasma suppliers and plasma fractionation centres
  • Acts as a focus point for information and contact
  • Maintains and develops contacts with non-governmental organisations (NGO’s) and competent authorities (e.g. EU DG Sanco, EMA, EDQM of the Council of Europe, WHO and US FDA)
  • Fosters interactions with patient organisations (e.g. World Federation of Haemophilia (WFH), International Patient’s Organisation for Primary Immunodeficiency (IPOPI), etc)
  • Gives support for education and training programmes to increase Good Manufacturing Practices (GMP) compliance, plasma supply and patient access, particularly in developing countries. This includes support for local programmes to improve policies to establishing the right diagnosis
  • Publishes position statements and publications to support key strategic issues and regulatory developments, relevant to its members
  • Organises international scientific workshops and educational seminars